Tag - PBYI

Developments

Puma Biotech anti-HER2 breast cancer drug approved in China

Puma Biotech (NASDAQ:PBYI) received approval to market neratinib in China via its licensing partner, CANbridge Pharmaceuticals. Neratinib, marketed as NERLYNX, is an extended adjuvant treatment for early stage HER2...

May 7, 2020

Markets

HCW starts Puma Biotechnology at buy; PT $15

H.C. Wainwright launched coverage of Puma Biotechnology (NASDAQ:PBYI) with a “buy” rating and $15 price target. The stock closed at $7.44 on Dec. 5. Puma has a marketed drug called Nerlynx, which was approved by the FDA...

December 6, 2019

Developments

Puma Biotech anti-HER2 breast cancer drug approved in Australia

Puma Biotech (NASDAQ:PBYI) received approval to market neratinib in Australia via its licensing partner, Specialised Therapeutics Asia, who has also submitted an application for regulatory approval in Singapore...

March 19, 2019

Tag - PBYI

Puma Biotech anti-HER2 breast cancer drug approved in China

HCW starts Puma Biotechnology at buy; PT $15

Puma Biotech anti-HER2 breast cancer drug approved in Australia

General

More